San Luis Obispo, California, USA, November 18, 2026
Fziomed, Inc., a medical technology company specializing in postsurgical adhesion-prevention biomaterials, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Dynavisc® Tendon Protector in the United States. The product is a fully synthetic, ready-to-use, absorbable gel designed to protect tendons, ligaments and skeletal muscle following surgical procedures. Developed using Fziomed’s proprietary dual-polymer technology, Dynavisc is applied directly to the surgical site after tendon repair, where it forms a temporary physical barrier between adjacent tissues during the healing process. The technology is intended to help reduce unwanted tissue adhesion and support tendon movement as recovery progresses. The regulatory clearance marks an important expansion of Fziomed’s U.S. medical device portfolio and introduces an established international biomaterial technology to the American surgical market. According to the company, Dynavisc has been commercially available internationally for more than a decade and has been used in more than 50,000 patients worldwide.
Dynavisc Creates a Protective Barrier After Tendon Surgery
Tendon repair procedures are performed to restore the function of damaged or injured tendons. However, postoperative healing can sometimes result in the formation of scar tissue and adhesions between tendons and surrounding tissues. These adhesions may restrict normal tendon gliding, reduce range of motion and interfere with functional recovery. In some cases, patients may experience persistent discomfort or require additional treatment to address movement limitations. Dynavisc is designed to help address this challenge through a temporary physical separation mechanism. The clear, absorbable gel is applied directly to exposed tissues following tendon repair, coating the surgical area and creating a protective layer between adjacent structures. This barrier is intended to remain in place during the healing process before being absorbed by the body. By limiting direct contact between tissues during recovery, the product may help reduce adhesion formation and support the restoration of normal tissue movement. Its ready-to-use formulation is designed to allow straightforward application within the surgical workflow. Dynavisc is a postsurgical tissue-protection device, not a drug or biological therapy, and its intended role is to provide physical separation during healing.
Dual-Polymer Technology and Clinical Experience
Fziomed developed Dynavisc using its proprietary dual-polymer technology platform, which forms the foundation of its synthetic, absorbable gel products. The technology is designed to create a temporary barrier without relying on animal-derived components. The company highlights its fully synthetic composition, ready-to-use presentation and ease of application as important product characteristics for surgeons. Dynavisc has been commercially available in international markets for more than ten years and, according to Fziomed, has been used in the treatment of over 50,000 patients globally. Its clinical history is supported by peer-reviewed publications evaluating outcomes such as tendon healing, tissue gliding and functional recovery following surgical procedures. These publications provide background evidence for the technology’s use in tendon-related applications, although the results of individual studies should be considered according to their specific designs and patient populations. The company believes the product can provide surgeons with an additional option for managing postoperative tissue adhesion risks. Orthopedic hand surgeon Dr. Nicholas Caggiano of Central Coast Orthopedic Medical Group highlighted the importance of preventing scar tissue from restricting tendon movement after repair and described the protective-barrier approach as a useful addition to surgical options. The product’s practical application is intended to integrate into existing tendon-repair procedures.
FDA Clearance Expands Fziomed’s U.S. Medical Device Portfolio
The FDA’s 510(k) clearance allows Dynavisc to be marketed in the United States for its cleared intended use. This regulatory milestone represents another step in Fziomed’s strategy to expand its biomaterial technologies across surgical specialties. The company has focused on developing products for postsurgical adhesion prevention in areas including spine, tendon, nerve, abdominal, pelvic and intrauterine procedures. Founded in 1996 and headquartered in San Luis Obispo, California, Fziomed reports that its biomaterial products have been used in more than one million patients worldwide and are marketed in over 70 countries under various brand names. Its portfolio is based on synthetic, absorbable gel formulations intended to provide temporary tissue separation during the body’s natural healing process.
The U.S. clearance of Dynavisc strengthens the company’s presence in the surgical biomaterials market and provides American surgeons with access to a product already used internationally. The clearance does not establish that the gel eliminates postoperative adhesions or guarantees improved functional outcomes for every patient. Its clinical value will depend on appropriate surgical use and the evidence supporting its performance in specific procedures. The development highlights the continuing role of absorbable biomaterials in addressing complications associated with surgical healing and improving options for postoperative tissue protection.
Source: Fziomed press release



